-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2699 Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Diseases, Myeloid Malignancies
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Talha Badar, MD1, Ehab L. Atallah, MD2, Antoine N. Saliba, MD3, Rory M. Shallis, MD4, Maximilian F. Stahl, MD5, Jan Philipp Bewersdorf, MD6, Guillerhme Sacchi De Camargo Correia, MD7*, Anand Ashwin Patel, MD8, Yasmin Abaza, MD9, Guru Subramanian Guru Murthy, MD10*, Adam S Duvall, MD11, Madelyn Burkart, MD12, Neil Palmisiano, MD, MS13, Danielle Bradshaw, MD14*, Vamsi K. Kota, MD14, Shira Dinner, MD9, Aaron D Goldberg, MD, PhD15 and Mark R. Litzow, MD3

1Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL
2Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
3Division of Hematology, Mayo Clinic, Rochester, MN
4Yale University School of Medicine, New Haven, CT
5Department of Medical Oncology, Dana-Farber Institute, Boston, MA
6Department of Internal Medicine, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven, CT
7Mayo Clinic, Florida
8Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
9Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
10Medical College of Wisconsin, Milwaukee, WI
11Department of Medicine, University of Chicago, Chicago, IL
12Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL
13Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
14Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA
15Memorial Sloan Kettering Cancer Center, New York, NY


TP53-mutated (m) acute myeloid leukemia (AML) is a high-risk disease with sub-optimal response to conventional therapies and portends a particularly worse outcome in patients with relapsed or refractory disease. In this study we analyzed the outcomes of patients with TP53m AML after first relapse or after primary induction failure.


We conducted this retrospective study through COMMAND (Consortium on Myeloid Malignancies and Neoplastic Diseases), a collaboration involving 10 US academic institutions. 366 patients with TP53m AML diagnosed between 2012-2021 were evaluated with 151 patients who had either primary refractory (87 [58%]) or relapsed (64 [42%]) disease and received further care, were the subject of this study. Continuous variables were summarized as median (range), while categorical variables were reported as frequency (percentage). Predictors of treatment response were assessed by Chi-square or Fisher’s exact test for nominal data and Wilcoxon rank-sum test for continuous variables. Event free survival (EFS) was estimated from time of diagnosis to progression or death. Overall survival (OS) from the date of first salvage until last follow up or death was evaluated by the Kaplan-Meier method with differences compared by the log-rank test. Cox proportional hazards regression models were used to find the univariate and multivariate predictors of OS. Multivariable models included all significant univariate predictors with p value <0.1.


Baseline characteristics

Baseline characteristics and treatment outcome are summarized in Table 1. The median age of the patients was 64 (range [R], 18-84) years and 59 (39%) patients were > 65 years of age. 21% of patients had therapy-related AML, 86% had complex cytogenetics (CG) and 9% of these patients had erythroid leukemia. Twenty-one (14%) patients relapsed after allogeneic stem cell transplantation (alloHCT). Co-mutations were observed in 45% of patients with the most frequently occurring (≥ 5% of patients) being ASXL1 (5%), TET2 (7%), DNMT3A (8%), RUNX1 (7%), RAS (7%), and JAK2 (8%) mutations. Salvage therapies were venetoclax-based (with hypomethylating agent [HMA] or low dose cytarabine [LDAC]) (46%), HMA +/- investigational agent (20.5%), intensive chemotherapy (IC; excluding CPX-351) (17%), other low intensity +/- investigational agent (11%) and CPX-351 (6%).


The rate of complete remission (CR) with or without count recovery (CRi) was 24% (n= 35) and 13% (n=20) were able to receive alloHCT after achieving response. We evaluated predictors of response (CR/CRi) using baseline variables. Age > 65 yrs (23% vs 77%, p=0.03) and secondary AML (15% vs 85%, p= 0.02) were significantly associated with an inferior response rate. Remaining variables were not significantly associated with response to salvage therapy.


The median EFS was 3.97 months (95% CI: 31.5-4.78) and median OS was 4.37 months (95% confidence interval [CI]: 3.58-5.15) (Figure 1a). In sub-group analysis, median OS (in months) based on salvage therapy was 3.23, 5.20, 3.93, 3.37 and 2.83 with venetoclax based, HMA +/- investigational agent, IC, other low intensity +/- investigational agent and CPX-351, respectively (p= 0.16) (Figure 1b). We did multivariate analysis (MVA) for OS, utilizing univariate predictors with p value <0.1. Achievement of CR/CRi (hazard ratio [HR]=0.57, 95% CI: 0.36-0.91; p=0.01) and alloHCT after salvage therapy (HR=0.45, 95% CI: 0.24-0.75; p= 0.03) retained significance for better OS. Complex CG (HR=1.83, 95% CI: 1.05-3.17; p= 0.03) and diagnosis of erythroid leukemia (HR=2.25, 95% CI: 1.22-4.17; p= 0.009) retained significance for inferior OS in MVA.


As expected, our study confirms the dismal outcome of patients with TP53m AML progressing on first line therapy, however alloHCT can significantly improve outcome even after salvage therapy in a subset of patients who achieve response and are eligible for alloHCT. Effective therapies are urgently needed to improve outcome of patients with TP53m AML.

Disclosures: Atallah: Takeda: Research Funding; BMS: Consultancy, Speakers Bureau; Blueprint: Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Servier: Consultancy; Novartis: Consultancy, Research Funding. Shallis: Bristol Myers Squibb and Gilead Sciences, Inc: Honoraria; Gilead Sciences, Inc.: Honoraria. Stahl: Boston Consulting: Consultancy; Novartis: Other: Advisory Board; Curis Oncology: Consultancy; GSK: Membership on an entity's Board of Directors or advisory committees; Sierra Oncology: Membership on an entity's Board of Directors or advisory committees; KYMERA: Membership on an entity's Board of Directors or advisory committees. Patel: Celgene/BMS: Research Funding; Pfizer: Research Funding; Servier/Agios: Research Funding; Kronos Bio: Research Funding; AbbVie: Consultancy. Abaza: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; ALX Oncology: Research Funding; Bristol Meyers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees. Duvall: Jazz Pharmaceuticals: Consultancy. Palmisiano: Genentech: Research Funding; AbbVie: Research Funding. Kota: Novartis: Honoraria; Pfizer Inc: Honoraria, Research Funding; Ariad: Honoraria; Incyte: Honoraria; Xcenda: Honoraria. Goldberg: Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Moderna, Novavax: Current equity holder in publicly-traded company; DAVA Oncology: Honoraria; Aprea, Aptose, AROG, Celularity, Pfizer, Prelude Therapeutics: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Litzow: Amgen: Research Funding; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding.

*signifies non-member of ASH